JP2016518321A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518321A5
JP2016518321A5 JP2016501214A JP2016501214A JP2016518321A5 JP 2016518321 A5 JP2016518321 A5 JP 2016518321A5 JP 2016501214 A JP2016501214 A JP 2016501214A JP 2016501214 A JP2016501214 A JP 2016501214A JP 2016518321 A5 JP2016518321 A5 JP 2016518321A5
Authority
JP
Japan
Prior art keywords
range
rfviii
formulation
ppm
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023357 external-priority patent/WO2014150477A1/en
Publication of JP2016518321A publication Critical patent/JP2016518321A/ja
Publication of JP2016518321A5 publication Critical patent/JP2016518321A5/ja
Pending legal-status Critical Current

Links

JP2016501214A 2013-03-15 2014-03-11 組み換え因子viii配合物 Pending JP2016518321A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US61/799,495 2013-03-15
US201361869191P 2013-08-23 2013-08-23
US61/869,191 2013-08-23
PCT/US2014/023357 WO2014150477A1 (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Publications (2)

Publication Number Publication Date
JP2016518321A JP2016518321A (ja) 2016-06-23
JP2016518321A5 true JP2016518321A5 (enExample) 2017-04-13

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501214A Pending JP2016518321A (ja) 2013-03-15 2014-03-11 組み換え因子viii配合物

Country Status (17)

Country Link
US (1) US20160030524A1 (enExample)
EP (1) EP2970430A4 (enExample)
JP (1) JP2016518321A (enExample)
KR (1) KR20150132449A (enExample)
CN (1) CN105209487A (enExample)
AU (1) AU2014237111B2 (enExample)
BR (1) BR112015022730A2 (enExample)
CA (1) CA2905739A1 (enExample)
HK (1) HK1213273A1 (enExample)
MX (1) MX2015012905A (enExample)
PE (1) PE20160121A1 (enExample)
RU (1) RU2015144076A (enExample)
SG (2) SG10201803999UA (enExample)
TW (1) TW201521761A (enExample)
UY (1) UY35412A (enExample)
WO (1) WO2014150477A1 (enExample)
ZA (1) ZA201507684B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
CN116949052A (zh) 2015-11-13 2023-10-27 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co CATHODE RAY TUBE AND METHOD FOR THE PRODUCTION THEREOF
ES2435141T3 (es) * 1999-02-22 2013-12-18 University Of Connecticut Nuevas formulaciones de factor VIII libres de albúmina
EP2110385A1 (en) * 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
SI1824988T1 (sl) * 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Similar Documents

Publication Publication Date Title
JP2016518321A5 (enExample)
JP2016515515A5 (enExample)
JP6910408B2 (ja) アネキシンvの製造プロセス
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
HRP20191843T1 (hr) Mikobakterijski antigenski pripravak
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
CA2746228C (en) Modified rsv f proteins and methods of their use
UA125223C2 (uk) СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING
MX2020009000A (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido.
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
JP2022533318A (ja) 気道感染の治療または予防のためのサブユニットワクチン
WO2015165374A1 (en) Methods and compositions for modulating the immune system with arginase i
MX2021004015A (es) Compuestos de aminoacidos y metodos de uso.
JP2009017881A5 (enExample)
EA200900373A1 (ru) Реконструированные сурфактанты, обладающие улучшенными свойствами
NZ700686A (en) Uses of casein compositions
NO20090178L (no) Vaksiner for malaria
JP2016520075A5 (enExample)
JP2012136518A5 (enExample)
EA201891143A1 (ru) Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
JP2015500827A5 (enExample)
RU2015144076A (ru) Композиции рекомбинантного фактора viii
WO2018134389A1 (en) Methods and compositions for treating infections
MX2020006328A (es) Composición inmunogénica.
JP2015519359A5 (enExample)